Literature DB >> 8499098

High-frequency monitoring for early detection of cisplatin ototoxicity.

S A Fausti1, J A Henry, H I Schaffer, D J Olson, R H Frey, G C Bagby.   

Abstract

Cisplatin can cause irreversible hearing loss initially detectable as impairment of high-frequency hearing with progression to lower frequencies. Many patients receiving cisplatin are too ill to tolerate lengthy audiometric testing. Therefore, a rapid and sensitive high-frequency monitoring strategy to detect cisplatin-induced ototoxicity is needed. Serial conventional (0.25 to 8 kHz) and high-frequency (> or = 8 kHz) threshold monitoring was performed in patients receiving cisplatin, resulting in 84% of ears showing hearing loss, of which 71% were detected first in frequencies of 8 kHz or greater. By analysis according to an individualized, specific high-frequency range, early identification of hearing loss occurred in 94% of ears showing change. This five-frequency procedure is a sensitive detector of ototoxicity and is proposed as an alternative monitoring protocol for patients receiving cisplatin who cannot tolerate extended testing.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499098     DOI: 10.1001/archotol.1993.01880180081015

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  21 in total

1.  Ototoxicity: the hidden menace.

Authors:  Manisha Bisht; S S Bist
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-02-23

2.  The protective effect of erdosteine against ototoxicity induced by cisplatin in rats.

Authors:  M Tayyar Kalcioglu; Ahmet Kizilay; Mukaddes Gulec; Erkan Karatas; Mustafa Iraz; Omer Akyol; Mucahit Egri; Orhan Ozturan
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-02       Impact factor: 2.503

Review 3.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

4.  Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer.

Authors:  Süleyman Yilmaz; Fatih Oktem; Emin Karaman
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-28       Impact factor: 2.503

5.  Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.

Authors:  Angela C Garinis; Douglas H Keefe; Lisa L Hunter; Denis F Fitzpatrick; Daniel B Putterman; Garnett P McMillan; Jeffrey A Gold; M Patrick Feeney
Journal:  Ear Hear       Date:  2018 Jan/Feb       Impact factor: 3.570

6.  Multivariate DPOAE metrics for identifying changes in hearing: perspectives from ototoxicity monitoring.

Authors:  Dawn Konrad-Martin; Kelly M Reavis; Garnett P McMillan; Marilyn F Dille
Journal:  Int J Audiol       Date:  2012-02       Impact factor: 2.117

7.  Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.

Authors:  Johnnie K Bass; Jie Huang; Arzu Onar-Thomas; Kay W Chang; Shaum P Bhagat; Murali Chintagumpala; Ute Bartels; Sridharan Gururangan; Tim Hassall; John A Heath; Geoffrey McCowage; Richard J Cohn; Michael J Fisher; Giles Robinson; Alberto Broniscer; Amar Gajjar; James G Gurney
Journal:  Pediatr Blood Cancer       Date:  2013-11-01       Impact factor: 3.167

8.  Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.

Authors:  Dawn Konrad-Martin; Kenneth E James; Jane S Gordon; Kelly M Reavis; David S Phillips; Gene W Bratt; Stephen A Fausti
Journal:  J Am Acad Audiol       Date:  2010-05       Impact factor: 1.664

9.  Safety of Extended Interval Tobramycin in Cystic Fibrosis Patients Less an 6 Years Old.

Authors:  Alexandria Arends; Rebecca Pettit
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

10.  Evaluation of noise-induced hearing loss by reference to the upper limit of hearing.

Authors:  I Morioka; K Miyashita; Y Gowa; S Takeda
Journal:  Int Arch Occup Environ Health       Date:  1995       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.